La vendita allo scoperto per SILO Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di SILO Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

SILO Pharma (NASDAQ:SILO) Azioni, Report sulle vendite allo scoperto

SILO Pharma

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

SILO Pharma Inc

Silo Wellness Inc

WIIM

DLTR

Dollar Tree shares are trading higher after JP Morgan maintained a Neutral rating on the stock an raised its price target from $70 to $82.

HDSN

Hudson Technologies shares are trading lower after the company reported worse-than-expected Q3 revenue results and Canaccord Genuity cut its price target on the stock from $8.75 to $8.

SPPL

Simpple Ltd shares are trading higher after the company announced its plan to regain NASDAQ compliance.

The Board of Directors approved an incremental $5 billion share repurchase authorization. With the addition of this new authorization, the company has $8.5 billion available under its share repurchase authorizations.&nbsp;

News

Buybacks

Marathon Petroleum Approved Incremental $5B Stock Buyback Authorization

Management

ADIL

Adial Pharmaceuticals Appoints Vinay Shah As Chief Financial Officer, Effective Nov. 16

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.verint.com%2F&amp;esheet=54147052&amp;newsitemid=20241105841152&amp;lan=en-US&amp;anchor=Verint%26%23174%3B&amp;index=1&amp;md5=cd382155b60eff877615bca4ef844957">Verint&#xAE;</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>), The CX Automation Company&#x2122;, today announced that a leading bank awarded Verint an $11 million contract for its AI-powered Agent Copilot Bot to assist 6,500 agents in their contact center.&#x2A;
The bank's contact center agents speak with customers for approximately 400 million minutes each year. The Verint AI-powered bot is designed to listen to these calls in the background and provide agents with real-time assistance, including coaching and guidance.
The bank conducted a pilot before awarding the contract and, based on the pilot result, the estimated annual savings from deploying the AI-powered bot is in the tens of millions of dollars.

Contracts

VRNT

Leading Bank Awards Verint $11M Contract For AI-Powered Agent Copilot Bot To Assist 6,500 Agents In Their Contact Center

BEAM

Beam Therapeutics shares are trading lower in reaction to a report indicating a patient in the company's CRISPR-based sickle cell treatment trial died.

SIMPPLE Outlines Plan To Regain Nasdaq Compliance, Including Potential Reverse Stock Split; Requests Hearing With Nasdaq To Seek Extension While Continuing Business Operations And Securing New Contracts

SI-BONE, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>), a&nbsp;Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for the iFuse Bedrock Granite&#x2122; (Granite) system, used for pelvic fixation and sacroiliac joint fusion in conjunction with lumbar spinal fusion procedures, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment status, which will be effective up to three years beginning January 1, 2025, allows patient access to new and innovative technology like Granite by providing an add-on payment to hospitals and ambulatory surgery centers supporting it.
As part of the TPT determination, CMS confirmed that a customary deduction from the add-on payment, known as a device offset, will not be applied to lumbar spinal fusion procedures involving pelvic fixation with Granite. This decision recognizes that Granite costs are not currently included in the existing facility payment amount for the procedures using this technology.

Biotech

General

SIBN

SI-BONE Receives Transitional Pass-Through Payment Status For iFuse Bedrock Granite System, Used For Pelvic Fixation And Sacroiliac Joint Fusion In Conjunction With Lumbar Spinal Fusion Procedures, Under The Medicare Hospital Outpatient Prospective Payment System

Simpple Ltd, A Leading Technology Provider Announced Its Plan To Regain NASDAQ Compliance

Guidance

BLDP

Ballard Power Systems Expects Revenue In 2024 To Be Weighted Towards Q4

The New York State Common Retirement Fund has significantly reduced its stake in Vistra Corp., according to a recent filing with the Securities &amp; Exchange Commission (SEC). This move was executed during the third quarter.
What Happened: The fund divested 43,440 shares, marking a 21.6% reduction in its Vistra Corp. holdings. Following this transaction, the fund retains 157,565 shares of the company&#8217;s stock, valued at $18,678,000 as per the latest SEC filing. This adjustment is part of the fund&#8217;s broader portfolio management strategy.
The change in the portfolio comes at a time when Vistra Corp&#8217;s year-to-date (YTD) returns have crossed 200%. As per Benzinga Pro, Vistra Corp was trading 0.24% higher on Tuesday during pre-market than its previous day close at $115.74.
See Also: <a href="https://www.benzinga.com/news/24/11/41705158/cathie-wood-says-trumps-ideas-on-eliminating-income-tax-and-imposing-tariffs-brings-back-vibes-of-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Says Trump&#8217;s Ideas On Eliminating Income Tax And Imposing Tariffs Brings Back Vibes Of &#8216;Early</a>
Why It Matters: Texas-based Vistra Corp. <a href="https://www.benzinga.com/insights/news/24/11/41715992/evaluating-vistra-against-peers-in-independent-power-and-renewable-electricity-producers-industry">stands as a major player</a> in the Independent Power and Renewable Electricity Producers industry. It is one of the largest power producers and retail energy providers in the U.S., especially after acquiring Energy Harbor in 2024. This acquisition expanded Vistra&#8217;s portfolio to include 41 gigawatts of nuclear, coal, natural gas, and solar power generation, alongside one of the world&#8217;s largest utility-scale battery projects.
Vistra&#8217;s retail electricity business serves approximately 5 million customers across 20 states, covering nearly a third of Texas&#8217;s electricity consumers. The company emerged as an independent entity in 2016 after the bankruptcy of Energy Future Holdings and further expanded by acquiring Dynegy in 2018.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41705665/palantir-technologies-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Palantir Technologies Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Top Analysts</a></li>
</ul>
Image via Midjourney
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Equities

Markets

New York State Common Retirement Fund Pares Vistra Corp Stake After Shares Rally Over 200% This Year

Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that ART26.12, the Company's lead clinical FABP inhibitor, has been accepted into the NIH Helping to End Addiction Long Term (HEAL) Initiative's Preclinical Screening Platform for Pain (PSPP).
The HEAL Initiative is an NIH-wide effort to accelerate scientific solutions to the overdose epidemic, including opioid and stimulant use disorders, and the crisis of pain. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=V0OIqyLfFcY5W7pjPpAuOgSxpFF0XIvawVscW4wbdwg7V_FhA3Ltt3AEUAniLYFzGCWmQxbGtaOlCTeoy9z_gw==">https://heal.nih.gov</a>.
The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models. The PSPP program accepts small molecules, biologics,&nbsp;devices,&nbsp;or natural products for evaluation, from researchers in academia and industry worldwide. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=V0OIqyLfFcY5W7pjPpAuOlGjlyIIOqxGCXGg7oAt6Z8k_ceVEneHLI1vwxQ_6cUhkiltyTw8QQT1pV5d70643HL2HPZdhRFfxJaV9YNhfRmH9nfw_RF6CKHtAfA4IrI-OAUc2GDix2f8AgJTeD-gGsZnWraYf9DQLl_KK0KyPERmmZ2qiTanbmibjkbPuCBhaatGJ8TqR2NK9mw7c9BFBPeEx1kzbGwZK3J_7R1YWB0=">https://heal.nih.gov/research/preclinical-translational/screening-platform</a>.
The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

ARTL

Artelo Biosciences Announces Acceptance Of ART26.12 Into The National Institutes Of Health's Helping To End Addiction Long Term Initiative's Preclinical Screening Platform For Pain

MPLX

MPLX shares are trading higher. The company reported Q3 financial results.

TCMD

Tactile Systems Tech shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.13) by 423.08 percent. The company reported quarterly sales of $14.800 million which missed the analyst consensus estimate of $23.556 million by 37.17 percent. This is a 46.33 percent decrease over sales of $27.575 million the same period last year.

Earnings

Earnings Misses

Ballard Power Systems Q3 2024 GAAP EPS $(0.68) Misses $(0.13) Estimate, Sales $14.800M Miss $23.556M Estimate

UL Solutions shares are trading higher after the company reported better-than-expect Q3 financial results.

<a href="https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss" title="https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss">https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss</a>

Patient In Beam Therapeutics' CRISPR Trial For Sickle Cell Disease Dies From Likely Chemotherapy Complications; Early Signs Of Gene Editing Effectiveness Observed In Other Participants

PHUN

Phunware Names Rahul Mewawalla As Chairman Of The Board To Lead Growth And Innovation In AI, Predictive Analytics, And Cloud Services

Vaccinex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical activity of immune checkpoint inhibitors in poorly immunogenic, HPV-negative, head and neck cancer (HNSCC). In a presentation at Society for Immunotherapy of Cancer's Annual Meeting (SITC) on November 8th, Vaccinex will present data from the Phase 2 KEYNOTE-B84 study (NCT04815720) for treatment of recurrent and metastatic disease as well as an independent study evaluating neoadjuvant treatment of resectable HNSCC (NCT03690986) showing that pepinemab combination treatments appear to induce mature lymphoid aggregates correlating with clinical benefit within immunotherapy resistant tumor populations, including HPV-negative and PD-L1 low HNSCC.

VCNX

Vaccinex Reports Improved Immunity Correlating With Clinical Benefit Of Pepinemab Combination Treatment At Society For Immunotherapy Of Cancer's Annual Meeting

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Silo Pharma&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) stock is rocketing higher on Tuesday after the developmental stage biopharmaceutical company <a href="https://www.nasdaq.com/press-release/silo-pharma-secures-exclusive-global-license-alzheimers-therapeutic-2024-07-16">secured a new global license</a>.



This license covers the development, manufacturing, and commercialization of its Alzheimer&rsquo;s drug SPC-14. It also intends to use the Food and Drug Administration&rsquo;s (FDA) streamlined 505(b)(2) pathway for speedy clinical trials.



Silo Pharma&nbsp;CEO&nbsp;Eric Weisblum said the following about the new license deal.




&ldquo;In our view, our exclusive license for SPC-14 gives us the potential to meet a large unmet medical need. If approved, we believe SPC-14 could bring hope and relief for many families and patients. Early pre-clinical studies have shown stress reduction and cognitive improvement.&rdquo;




<h2>What This Means for SILO Stock</h2>



Development of a new Alzheimer&rsquo;s drug is a big deal. The market for Alzheimer&rsquo;s disease therapeutics is expected to be more than 30.8 billion&nbsp;by 2033. This new treatment could earn Silo Pharma a share of that market.



SILO stock is up 122.5% as of Tuesday morning. That comes with some 15 million shares traded. This is well above the company&rsquo;s daily average trading volume of about 257,000 shares. Investors will note the stock was down 29.6% year-to-date when markets closed yesterday.



Investors will want to stick around for even more of the most recent stock market stories on Tuesday!



We have all of the hottest market news traders need to know about today! That includes the biggest pre-market stock movers and more of the latest stock market coverage! You can catch up on all of that at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-16th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Tuesday</a></li>



<li><a href="https://investorplace.com/2024/07/wolfe-research-says-to-bet-big-on-coinbase-coin-stock-if-trump-wins-in-november/">Wolfe Research Says to Bet Big on Coinbase (COIN) Stock If Trump Wins in November</a></li>



<li><a href="https://investorplace.com/2024/07/dear-mstr-stock-fans-mark-your-calendars-for-july-27/">Dear MSTR Stock Fans, Mark Your Calendars for July 27</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-123-today/">Why Is Silo Pharma (SILO) Stock Up 123% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Silo Pharma (SILO) Stock Up 123% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenpro Capital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) stock is dropping on Tuesday after the financial consulting and corporate advisory services company&rsquo;s shares underwent a large rally during the prior day of trading.



This saw shares of GRNQ stock close out normal trading hours on Monday up more than 34%. That came with heavy trading as over 10 million units moved yesterday. To put that number in perspective, the daily average trading volume for Greenpro Capital shares is around 183,000.



This rally didn&rsquo;t come without any news. The catalyst behind it was Greenpro Capital announcing a new strategic partnership. This brings together Greenpro Capital, its subsidiary Green-X and Bank Islam Trust Company.



Greenpro Capital CEO Dr. CK Lee <a href="https://www.nasdaq.com/press-release/greenpro-capital-corp-and-green-x-corp-forms-strategic-alliance-bank-islam-trust">said this about the strategic alliance</a>.




&ldquo;We are extremely excited to have&nbsp;Bank Islam Trust&nbsp;as our strategic partner to penetrate the Muslim and&nbsp;Middle East&nbsp;communities. There is a huge demand for digital asset investments from the&nbsp;Middle East, and we will structure our STO and RWA assets as alternative investment products to cater to their demand.&rdquo;




<h2>GRNQ Stock Movement Today</h2>



Considering the rally yesterday, it makes sense that GRNQ stock would give up some of those gains today. That has the stock falling 19.1% as of Tuesday morning. Traders will note that GRNQ shares were down 5.6% year-to-date when markets closed yesterday.



Today&rsquo;s stock market movement comes with some 230,000 shares of GRNQ on the move. That&rsquo;s already above Greenpro Capital&rsquo;s daily average trading volume.



Investors will want to keep reading for more of the biggest stock market stories on Tuesday!



We have all of the hottest stock market happenings to report on today! That includes the latest news for Autonomix Medical&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/amix-stock-quote/">AMIX</a>) stock, Conduit Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock and Silo Pharma&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) stock this morning. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-autonomix-medical-amix-stock-down-17-today/">Why Is Autonomix Medical (AMIX) Stock Down 17% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-conduit-pharmaceuticals-cdt-stock-up-73-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-123-today/">Why Is Silo Pharma (SILO) Stock Up 123% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-greenpro-capital-grnq-stock-down-19-today/">Why Is Greenpro Capital (GRNQ) Stock Down 19% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Greenpro Capital (GRNQ) Stock Down 19% Today?

Silo Pharma files to sell 1.04M shares of common stock for holders

Silo Pharma, Aeon Biopharma, and NaaS Technology are the 3 Penny Stocks to watch on July 18, based on&nbsp;TipRanks' Penny Stock Screener tool. Pen...

3 Penny Stocks to Watch Now, 7/18/24

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Developmental-stage pharmaceutical firm Silo Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) &mdash; which specializes in both traditional and psychedelic therapeutics to address stress-induced psychiatric disorders &mdash; saw its shares rise dramatically on Thursday. Earlier this morning, the company announced a partnership to develop an intranasal drug to address post-traumatic stress disorder (PTSD). The news and the large addressable market appears to have catapulted SILO stock.



According to Silo&rsquo;s <a href="https://finance.yahoo.com/news/silo-pharma-resyca-bv-partner-122500980.html">press release</a>, the pharmaceutical firm entered into a partnership with Resyca BV, a medical technology provider. Resyca itself is a joint venture which manufactures a formulation-specific microchip-based spray system &mdash; a system that undergirds Silo&rsquo;s lead candidate called SPC-15. This therapeutic addresses PTSD through &ldquo;cutting-edge nose-to-brain drug dispersion,&rdquo; explained Silo CEO Eric Weisblum.



In addition, the head executive added that &ldquo;this delivery method could increase the drug&rsquo;s concentration in the brain to deliver a faster onset of therapeutic benefit and optimized safety for PTSD patients.&rdquo;



Importantly, Silo and Resyca have developed a plan to set the framework for pre-human clinical trials. Such trials are necessary before the partnership can apply for an investigational new drug (IND) from the Food and Drug Administration (FDA) to conduct human trials.



<h2>Growing Need for PTSD Solutions Fuels the Surge in SILO Stock</h2>



Naturally, the anticipation of a regulatory green light has contributed to the explosive sentiment in SILO stock. A few days ago, the underlying pharma made headlines when it announced a <a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-123-today/">licensing deal</a> for the development of SPC-14, a therapeutic for Alzheimer&rsquo;s.



Regarding today&rsquo;s jump in SILO stock, the growing need for addressing PTSD has helped positively shift the underlying corporate narrative. Prior to the series of key developments, Silo suffered a significant drop in equity value in the past one-year period. Now, in the past five sessions, SILO has gained 260%.



According to Grand View Research, the global PTSD treatment market size <a href="https://www.grandviewresearch.com/industry-analysis/post-traumatic-stress-disorder-treatment-market-report">reached a valuation of $915.5 million in 2021</a>. Experts project a compound annual growth rate (CAGR) of 4.7% from 2022 to 2030. At the culmination point, the sector could generate revenue of $1.4 billion. However, it&rsquo;s also possible that this projection may be understated.



Presently, about one in five adults in the U.S. experience some form of <a href="https://magazine.howard.edu/stories/the-growth-of-mental-health-awareness#:~:text=and%20self%2Dcare.-,With%201%20in%205%20adults%20in%20the%20United%20States%20experiencing,wellness%2C%20especially%20on%20social%20media.">mental illness</a>. Further, as people &mdash; especially younger generations &mdash; become more vocal about mental wellness issues, demand for treatment solutions may rise. That&rsquo;s also another potential catalyst for SILO stock.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-60-today/">Why Is Silo Pharma (SILO) Stock Up 60% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Silo Pharma (SILO) Stock Up 60% Today?

Silo Pharma stock plummets on $2.1M registered direct offering priced ATM

Silo Pharma announces partnership with global CRO for central nervous system homing peptide

Silo Pharma files for secondary stock offering

Silo Pharma ( ($SILO) ) has shared an update. Silo Pharma, Inc. has released a presentation outlining its strategic direction and product pipeline,...

Silo Pharma Outlines Strategic Direction and Innovative Pipeline

Silo Pharma (SILO) announced promising results from recent sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgi...

Silo Pharma reports results in sterilization, dissolution testing of SP-26

AEON

AMIX

GRNQ

NAAS

SILO

Screenshot 2024-05-21 at 6.46.56 PM

ATAI

FTRP

Revolutionizing Mental Healthcare With The Rise Of Ketamine And Psychedelic Therapies

Press Releases

Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders

Health Care

Legal

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Comments

SILO Pharma

Vendite allo scoperto

SILO Pharma (NASDAQ:SILO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO